Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System AtrophyBOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ...
The first participant has been dosed in an investigator-led Phase 2 trial testing pegsebrenatide as a potential treatment for ...
MedPage Today on MSN
Brain Changes Tied to Single Psilocybin Dose; 50 Days to See Neurology; APOE4 and MS
News and commentary from the world of neurology and neuroscience ...
5h
Illness is no limit: Student with severe genetic conditions emerges as a top Temasek Poly graduate
Ms Gwyn Lim Qi Zheng (right) was one of the recipients of Temasek Polytechnic's Ngee Ann Kongsi Most Outstanding Overcomer ...
Neuraly, Inc., a wholly owned subsidiary of D&D Pharmatech, Inc. (KOSDAQ: 347850), announced that the first patient has been dosed in a Phase 2 Investigator-Initiated Trial (IIT) evaluating ...
Morning Overview on MSN
Study links white matter damage to repeating repair-disease cycles
When myelin, the insulating sheath around nerve fibers, is damaged in the brain’s white matter, the body launches an inflammatory response designed to fix the problem. A pair of studies published in ...
Nearly every woman with breast cancer has at least one menopausal symptom. Yet many patients feel their quality-of-life needs ...
SussexWorld on MSN
Fernhurst campaigner urges awareness of rare dementias
See the latest news from Your World at https://www.sussexexpress.co.uk/your-world ...
A 16-year MRI study reveals that lower visceral fat is linked to slower brain atrophy and better cognition, mediated by ...
DNA damage from inflammation outpaces the cells’ ability to self-repair. The finding, in human brain cells and mice, could ...
Two experimental drug molecules promoted myelin repair in MS disease models, pointing toward a possible future route for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results